Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 4:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: L-Histidine Clear all
Completed Not applicable Interventional Results available

The Role of Serotonin in Hot Flashes After Breast Cancer

NCT00228943
View directory record Official record
Conditions
Breast Cancer
Interventions
Acute tryptophan depletion, Half-strength tryptophan depletion (Control)
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Sep 23, 2026, 4:19 AM EDT
Completed Phase 2 Interventional

Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate

NCT00069017
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
MEDI-522, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
29
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2007 · Synced Sep 23, 2026, 4:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety of Graded-Dose of Histidine in Humans

NCT04142294
View directory record Official record
Conditions
Healthy
Interventions
Histidine
Dietary Supplement
Lead sponsor
Cornell University
Other
Eligibility
21 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2022 · Synced Sep 23, 2026, 4:19 AM EDT
Not yet recruiting Phase 2 Interventional

DaxibotulinumtoxinA for Blepharospasm

NCT07489430
View directory record Official record
Conditions
Blepharospasm of Both Eyelids, Blepharospasm of Left Eyelid, Blepharospasm of Right Eyelid, Blepharospasm, Benign Essential, Blepharospasm
Interventions
Botulinum Neurotoxin Type A
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 23, 2026, 4:19 AM EDT
Completed Phase 2 Interventional Results available

A Study In Adults With Moderate To Severe Dermatomyositis

NCT03181893
View directory record Official record
Conditions
Dermatomyositis
Interventions
PF-06823859 low, Placebo Arm, PF-06823859 high
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Sep 23, 2026, 4:19 AM EDT
Active, not recruiting Phase 2 Interventional

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

NCT06172127
View directory record Official record
Conditions
HER2-positive Breast Cancer
Interventions
Trastuzumab deruxtecan, Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection, Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection
Drug
Lead sponsor
MedSIR
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 23, 2026, 4:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Copper Histidine Therapy for Menkes Diseases

NCT00001262
View directory record Official record
Conditions
Kinky Hair Syndrome
Interventions
Copper Histidine
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1990 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Sep 23, 2026, 4:19 AM EDT
Terminated Phase 1 Interventional

Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT02277184
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
Ficlatuzumab, Cisplatin, Intensity Modulated Radiotherapy (IMRT)
Drug · Radiation
Lead sponsor
Julie E. Bauman, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 23, 2026, 4:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

NCT02592551
View directory record Official record
Conditions
Mesothelioma
Interventions
MEDI4736, Tremelimumab, no other name
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Sep 23, 2026, 4:19 AM EDT
Completed Phase 3 Interventional

Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency

NCT00811785
View directory record Official record
Conditions
Menkes Disease, Occipital Horn Syndrome, Unexplained Copper Deficiency
Interventions
Copper Histidine
Drug
Lead sponsor
Cyprium Therapeutics, Inc.
Industry
Eligibility
Up to 80 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Sep 23, 2026, 4:19 AM EDT
Completed Phase 2 Interventional Results available

Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

NCT01151046
View directory record Official record
Conditions
Her2 Negative Breast Cancer Patients
Interventions
MM-121, Placebo, Exemestane
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
18
States / cities
Birmingham, Alabama • Glendale, Arizona • Anaheim, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Sep 23, 2026, 4:19 AM EDT
Recruiting Phase 2 Interventional

Neurovascular Transduction During Exercise in Chronic Kidney Disease

NCT02947750
View directory record Official record
Conditions
Renal Insufficiency, Chronic
Interventions
6R-BH4, 6R-BH4 placebo, Folic acid, Exercise training, Stretching, Histidine and beta-alanine supplementation, Histidine and beta-alanine placebo
Drug · Other · Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia • Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 23, 2026, 4:19 AM EDT
Completed Phase 2 Interventional Results available

Mechanistic Approach to Preventing Atrophy and Restoring Function in Older Adults

NCT02145949
View directory record Official record
Conditions
Muscle Atrophy, Quality of Life
Interventions
Essential Amino Acids (EAA), Placebo (Alanine)
Drug
Lead sponsor
University of Oregon
Other
Eligibility
50 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Sep 23, 2026, 4:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab

NCT02859441
View directory record Official record
Conditions
Von Hippel-Lindau Syndrome
Interventions
Ranibizumab, E10030
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 23, 2026, 4:19 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Histaminergic Basis of Fatigue in Multiple Sclerosis

NCT04764383
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
L-Histidine, Placebo, Lodosyn
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Sep 23, 2026, 4:19 AM EDT
Recruiting Phase 2 Interventional

The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD

NCT05440422
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Cardiovascular Disease, Premature Atherosclerosis
Interventions
anifrolumab, Placebo
Drug · Other
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 23, 2026, 4:19 AM EDT
Not yet recruiting Phase 4 Interventional

Epoprostenol Plus Conventional Therapy in COld and Frostbite Injury (ECCO)

NCT07424378
View directory record Official record
Conditions
Frostbite
Interventions
Standard of care plus Epoprostenol infusion for 8 hours (hrs) per day up to 5 days maximum, Standard of Care + Placebo (Normal Saline)infusion for 8 hours per day up to 5 days maximum
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 23, 2026, 4:19 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of ASCT-83 in Healthy Adults

NCT07363395
View directory record Official record
Conditions
Neuropathic Pain
Interventions
ASCT-83, Placebo
Drug
Lead sponsor
Alcamena Stem Cell Therapeutics
Industry
Eligibility
18 Years to 64 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 23, 2026, 4:19 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of Intravenous ZMA001 in Healthy Subjects

NCT05967299
View directory record Official record
Conditions
Pulmonary Arterial Hypertension PAH
Interventions
Placebo Cohort 1 (1.5 mg/kg/dose) only, ZMA001 (BC-NKA-20008)
Other · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 60 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 23, 2026, 4:19 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S

NCT01556945
View directory record Official record
Conditions
Malaria, Falciparum
Interventions
FMP1/AS02, RTS,S/AS02, AS02 adjuvant alone, Malaria challenge
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Sep 23, 2026, 4:19 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer

NCT03241810
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Seribantumab, Fulvestrant, Placebo
Drug
Lead sponsor
Elevation Oncology
Industry
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Chandler, Arizona • Fayetteville, Arkansas • Beverly Hills, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Sep 23, 2026, 4:19 AM EDT
Completed No phase listed Observational

Non-Invasive Assessment of Skeletal Muscle Loss in Cancer Patients - Phase II

NCT01694602
View directory record Official record
Conditions
Cachexia
Interventions
(non-radioactive) Oral deuterated 3-methylhistidine (D-3MH)
Biological
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Sep 23, 2026, 4:19 AM EDT
Completed Phase 4 Interventional

TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

NCT05002998
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Teprotumumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
7
States / cities
Beverly Hills, California • Los Angeles, California • Palo Alto, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 23, 2026, 4:19 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)

NCT02569632
View directory record Official record
Conditions
Meningococcal Infections
Interventions
Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals)
Biological
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Oakland, California • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 23, 2026, 4:19 AM EDT